Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical Prognostic Factors in Gastric Cancer in Chinese Patients: Experience from the Cancer Hospital/Institute, Chinese Academy of Medical Sciences Yuankai.

Published byJuniper Holt Modified over 9 years ago

Similar presentations

Presentation on theme: "Clinical Prognostic Factors in Gastric Cancer in Chinese Patients: Experience from the Cancer Hospital/Institute, Chinese Academy of Medical Sciences Yuankai."— Presentation transcript:

1 Clinical Prognostic Factors in Gastric Cancer in Chinese Patients: Experience from the Cancer Hospital/Institute, Chinese Academy of Medical Sciences Yuankai Shi, M.D. Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences (CAMS)

2 Background 4th most common cancer, 2nd most common cause of death, 2/3 patients in developing countries, 42% of them in China Gastric cancer worldwide in 2002: Parkin DM, et al. CA Cancer J Clin. 2005;55:74

3 5-year overall survival: 15%-54% Parkin DM, et al. CA Cancer J Clin. 2005;55:74

4 Gastric cancer in China in 2005  Incidence: 376,000 new cases 376,000 new cases Third most common cancer Third most common cancer  Mortality: 24.71/10 24.71/10 5 Third from cancer Third cause of death from cancer Behind Lung cancer and Liver cancer Behind Lung cancer and Liver cancer http://www.moh.gov.cn

5 Objective   To evaluate the therapeutic effects and prognostic factors in patients with operable gastric cancer   To construct a prognostic model

6 Materials and methods  Identify prognostic factors with data from 1043 pts treated with combined modality therapy based on gastrectomy, between 1999 and 2002, in the Cancer Hospital, CAMS  Construct prognostic model with data from 1284 pts with combined modality treatment based on gastrectomy, between 1999-2006, in the Cancer Hospital, CAMS  Statistical analysis Life Table, Cox hazard proportional model, Logistic regression model Life Table, Cox hazard proportional model, Logistic regression model

7 Results 5-year 39% 15% 5-year OS 100% 91% 84% 61% 33% 19% 5%  Median survival: 39.5 mo  median relapse-free survival: 22.7 mo  5-y OS: 39%  5-y RFS: 15% 1043 pts with operable gastric cancer median follow-up: 51.6 mo

8 Univariate analysis in 1043 pts

9

10 Independent prognostic factors

11 All pts n=1284 Training sample n=963 Testing sample n=321 Randomized Prognostic equation Prognostic index Prognostic model Construct Validate

12 Fig. Overall survival (OS) and relapse-free survival (RFS) for 1284 patients. Overall survival and relapse-free survival Median follow-up: 35.7 mo 5-y OS: 40% 5-y RFS: 12%

13 Univariate analysis in 1284 pts

14

15 Independent prognostic factors of OS in training sample

16 Prognostic model LNM: Lymphonode metastases; PCI: peritoneal cavity involvement. FactorsScore Age>60y1 Proximal1 Stage Ⅲ / Ⅳ 2 LNM ratio>1/3 2 PCI2 Risk group Score Low risk (L) 0-1 Low intermediate (LI) 2-3 High intermediate (HI) 4-5 High risk (H) 6-8

17 Risk model defined by prognostic index

18 Risk model in age group 5-year OS 82% 60% 27% 7% 5-y OS 81% 48% 20% 0 P<0.001 5-y OS 82% 60% 27% 7%

19 Risk model in stage

20 Survival curve according to risk model LI L L

21 Risk model in treatment

22 Discussion Lagarde SM, et al. J Clin Oncol, 2006, 24:4347

23 AuthorTimeNPatients Independent prognostic factors Zhan2005497curative Stage, Size, Perioperative chemotherapy Yolota2002697operable Site, T category, LNM Schwarz20071377operableIIIA-IV Age, Site, Number of LNM, T category, Sex The present study1043operable Age, Site, Size, Stage, Ratio of LNM, PCI, Curative resection, Combined therapy Comparison in gastric cancer prognostic factors Zhan YQ, et al. Ai Zheng 2005,24:596; Yokota T, et al. Anticancer Res 2002,22:3673; Schwarz RE et al. Ann Surg Oncol 2007,14:317

24 Conclusion  This risk model could identify various outcomes in pts with the same stage from IB to IV  This risk model also could identify different outcomes in pts with the same treatment status  Prospective study are warranted to validate these findings.

25 Acknowledgements Dept. of Abdominal Surgical Oncology Zhi-xiang Zhou Zhi-xiang Zhou Hai-zeng Zhang Hai-zeng Zhang Yi Shan Yi Shan Ping Zhao Ping Zhao Xiang Wang Xiang Wang Jian-xiong Wu Jian-xiong Wu Yong-fu Zhao Yong-fu Zhao Dept. of Medical Oncology Jing Wang Jing Wang Jin-wan Wang Jin-wan Wang Hong-gang Zhang Hong-gang Zhang Yu-sheng Li Yu-sheng Li Jing Huang Jing Huang Xiao-hui He Xiao-hui He Xiao-hong Han Xiao-hong Han Dept. of Pathology Xun Zhang Xun Zhang Yan Song Yan Song Shang-mei Liu Shang-mei Liu Dept. of Imaging Diagnosis Chun-wu Zhou Chun-wu Zhou Li-ming Jiang Li-ming Jiang Zhu Wang Zhu Wang

26 Thank you for your attention!

Download ppt "Clinical Prognostic Factors in Gastric Cancer in Chinese Patients: Experience from the Cancer Hospital/Institute, Chinese Academy of Medical Sciences Yuankai."

Similar presentations

Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs E. Efthimiou, S Mudan E. Efthimiou, S Mudan On behalf of the Sarcoma Group.

Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs E. Efthimiou, S Mudan E. Efthimiou, S Mudan On behalf of the Sarcoma Group.
State-of-the-art in the Surgical Treatment of Gastric Cancer in Shanghai Department of Surgery Rui Jin Hospital School of Medicine, SJTU.

State-of-the-art in the Surgical Treatment of Gastric Cancer in Shanghai Department of Surgery Rui Jin Hospital School of Medicine, SJTU.
Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.

Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.
 DISCUSSION Number of resected lymph nodes in esophageal surgery has been previously discussed as for its probable impact on patients’ survival [4]. The.

 DISCUSSION Number of resected lymph nodes in esophageal surgery has been previously discussed as for its probable impact on patients’ survival [4]. The.
IMPACT OF TUMOR MORCELLATION ON THE NATURAL HISTORY OF UTERINE LEIOMYOSARCOMA César Serrano, Titilope Oduyebo, Judith Manola, Yang Feng, Michael G. Muto,

IMPACT OF TUMOR MORCELLATION ON THE NATURAL HISTORY OF UTERINE LEIOMYOSARCOMA César Serrano, Titilope Oduyebo, Judith Manola, Yang Feng, Michael G. Muto,
Casulo C et al. Proc ASH 2013;Abstract 510.

Casulo C et al. Proc ASH 2013;Abstract 510.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.

ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
2-6-20151 Analysis of risk factors predicting time to development of brain metastases presented at the 44 th Annual ASCO Meeting, June 2 2008, McCormick.

Analysis of risk factors predicting time to development of brain metastases presented at the 44 th Annual ASCO Meeting, June , McCormick.
CO-I KNTM/K i CzS M. Sklodowska-Curie Memorial Cancer Center-Institute of Oncology Medical University of Warsaw; Warsaw, POLAND Medical University of Gdansk;

CO-I KNTM/K i CzS M. Sklodowska-Curie Memorial Cancer Center-Institute of Oncology Medical University of Warsaw; Warsaw, POLAND Medical University of Gdansk;
Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.

Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.

Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.

References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.
These slides were released by the speaker for internal use by Novartis.

These slides were released by the speaker for internal use by Novartis.
Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.

Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.
Role of biologic therapy in the treatment of unresectable appendiceal epithelial neoplasms Eng C 1, Overman M 1, Fournier K 2, Royal R 2, Ohinata A 1,

Role of biologic therapy in the treatment of unresectable appendiceal epithelial neoplasms Eng C 1, Overman M 1, Fournier K 2, Royal R 2, Ohinata A 1,
Lymphadenectomy in Epithelial Ovarian Cancer

Lymphadenectomy in Epithelial Ovarian Cancer
Multimodality therapy for locally advanced thymomas: a cohort study of prognostic factors from a European multicentric database Dr. GIOVANNI LEUZZI Department.

Multimodality therapy for locally advanced thymomas: a cohort study of prognostic factors from a European multicentric database Dr. GIOVANNI LEUZZI Department.

Similar presentations

Ads by Google